// App-Quantinova.ai

: A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Researchers

Presenter

  • Ing S Tiong

Principal Investigators

  • Devendra Hiwase

  • Emad Uddin Abro

  • Ashish Bajel

  • Emma Palfreyman

  • Sun Loo

  • Shaun Fleming

  • Chun Yew Fong

  • Tse-Chieh Teh

  • Adam Ivey

  • Andrew H Wei

Medical Centers

  • Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia

  • Box Hill Hospital, Victoria, Australia

  • The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

  • The Alfred Hospital and Monash University, Melbourne, Australia

  • Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia

  • Royal Darwin Hospital, Northern Territory, Australia

  • Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Australia

  • Department of Haematology, Royal Adelaide Hospital, Adelaide, Australia

  • Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

  • Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Hematocrit

  • Isocitrate dehydrogenase 1

Drug/Treatment

  • Venetoclax

  • ara-c

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved